Integra LifeSciences Holdings Corporation (IART)
IART trades on Nasdaq in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/917520/000091752026000011/0000917520-26-000011-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | IART on Nasdaq |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000917520 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.6B |
| Net income | -$516.5M |
| Operating income | -$493.4M |
| Net margin | -31.6% |
| Operating margin | -30.2% |
| Revenue growth | +1.5% |
| Cash | $235.0M |
| Total assets | $3.6B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-23 |
| Cash and burn | $252.3M cash; operating cash flow $35.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 77,800,976 (2026-10-22); 77,892,111 a year earlier; 78,175,803 three years earlier. | Cover page 2026-10-22 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-02-26 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Florham Park, New Jersey, United States | PCAOB Form AP 2026-03-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $102K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $411.2M | $14.9M | $96.0M | $252.3M | $697.5M | $1.7B | 10-Q 2026-10-23 |
| Q2 2026 2026-06-30 | $418.8M | $4.5M | $22.8M | $214.4M | $707.2M | $1.6B | 10-Q 2026-07-29 |
| Q1 2026 2026-03-31 | $391.9M | -$4.6M | $9.8M | $236.8M | $716.9M | $1.6B | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | $434.9M | -$1.7M | $11.8M | $235.0M | $726.6M | $1.6B | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $402.1M | -$5.4M | $40.9M | $232.2M | $736.3M | $1.6B | 10-Q 2026-10-23 |
| Q2 2025 2025-06-30 | $415.6M | -$484.1M | $8.9M | $217.9M | $745.9M | $1.6B | 10-Q 2026-07-29 |
| Q1 2025 2025-03-31 | $382.7M | -$25.3M | -$11.3M | $239.1M | $755.6M | $1.6B | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | $442.6M | $19.4M | $50.7M | $246.4M | $760.5M | $1.6B | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-02-26 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-10-23 |
| Latest current report | 8-K | 2026-10-21 |
| Latest proxy | DEFA14A | 2026-05-05 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +7.3% |
| 1 month | +4.0% |
| 3 months | -21.1% |
| Year to date | +15.9% |
| 1 year | +19.6% |
| From 52-week high | -27.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IRMD | iRadimed Corporation | $84.84 | -0.60% | $1.1B |
| SGP | SpyGlass Pharma Inc. | $32.24 | -1.95% | $1.1B |
| DRTS | Alpha Tau Medical Ltd. | $11.97 | -10.54% | $1.1B |
| SIBN | SI-BONE Inc. | $23.41 | -0.13% | $1.1B |
| ATEC | Alphatec Holdings Inc. | $6.78 | -4.10% | $1.1B |
| TNDM | Tandem Diabetes Care Inc. | $18.48 | -7.92% | $1.3B |
| AORT | Artivion Inc. | $18.47 | -3.30% | $901.1M |
| NVCR | NovoCure Limited | $11.30 | -4.48% | $1.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier